Eric Davis - BioMarin Pharmaceutical Insider

BMRN -- USA Stock  

USD 97.84  1.56  1.62%

Mr. G. Eric Davis serves as Executive Vice President, General Counsel and Secretary of Biomarin Pharmaceutical Inc. He joined BioMarin in March 2004 and currently serves as our Executive Vice President, General Counsel and Secretary. From December 2005 to March 2016, Mr. Davis served as our Senior Vice President, General Counsel and Secretary and from 2004 to December 2005, Mr. Davis served as our Vice President, General Counsel and Secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings LLP, where he served on the firms national securities practice committee. Mr. Davis has represented public and private companies and VC and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual propertyrelated business transactions. His experience involves a variety of industries, including biotechnology and life sciences
Age: 46  SVP Since 2016      
Davis received a B.A. in political economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.

Management Efficiency

The company has return on total asset (ROA) of (2.21) % which means that it has lost $2.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (4.4) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.19 B in liabilities with Debt to Equity (D/E) ratio of 41.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioMarin Pharmaceutical has Current Ratio of 2.77 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 3 records

SVP Since

David NovackDynavax Technologies Corporatio
Bob BrownDicerna Pharmaceuticals
Robert CoffmanDynavax Technologies Corporatio

Entity Summary

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was founded in 1996 and is headquartered in San Rafael, California. BioMarin Pharmaceutical operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 2581 people.BioMarin Pharmaceutical (BMRN) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 2,581 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

BioMarin Pharmaceutical Leadership Team

Elaine Heron, Independent Director
Dennis Slamon, Director
Henry Fuchs, Executive Vice President and Chief Medical Officer
Robert Hombach, Independent Director
Brian Mueller, Chief Accounting Officer, Group VP and Controller
Bryan Lawlis, Independent Director
JeanJacques Bienaime, Chairman of the Board, CEO
Jeff Ajer, Executive Vice President Chief Commercial Officer
Richard Meier, Independent Director
Willard Dere, Director
Daniel Spiegelman, CFO, Executive Vice President
Kathryn Falberg, Director
Eric Davis, Sr. VP, General Counsel and Secretary
Pierre Lapalme, Independent Chairman of the Board
Robert Baffi, Executive VP of Technical Operations
Alan Lewis, Independent Director
Richard Ranieri, Senior Vice President - Human Resources and Corporate Affairs
David Pyott, Independent Director
Michael Grey, Independent Director

Stock Performance Indicators

Current Sentiment - BMRN

BioMarin Pharmaceutical Investor Sentiment

Most of Macroaxis users are currently bullish on BioMarin Pharmaceutical. What is your opinion about investing in BioMarin Pharmaceutical? Are you bullish or bearish?
98% Bullish
2% Bearish

BioMarin Pharmaceutical Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for BioMarin Pharmaceutical and Endocyte. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.